These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19145277)

  • 1. Is behavioral therapy plus antimuscarinic better than drug alone to treat overactive bladder?
    Chancellor MB; Hasenau DL
    Rev Urol; 2008; 10(4):306-8. PubMed ID: 19145277
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Combined Behavioral and Drug Therapy for Overactive Bladder Symptoms in Men: A Randomized Clinical Trial.
    Burgio KL; Kraus SR; Johnson TM; Markland AD; Vaughan CP; Li P; Redden DT; Goode PS
    JAMA Intern Med; 2020 Mar; 180(3):411-419. PubMed ID: 31930360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of an α
    Herschorn S; Tarcan T; Jiang YH; Chung E; Abdul Hadi F; Steup A; Sumarsono B
    Neurourol Urodyn; 2024 Mar; 43(3):604-619. PubMed ID: 38291827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral versus drug treatment for overactive bladder in men: the Male Overactive Bladder Treatment in Veterans (MOTIVE) Trial.
    Burgio KL; Goode PS; Johnson TM; Hammontree L; Ouslander JG; Markland AD; Colli J; Vaughan CP; Redden DT
    J Am Geriatr Soc; 2011 Dec; 59(12):2209-16. PubMed ID: 22092152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
    Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
    Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study.
    Akino H; Namiki M; Suzuki K; Fuse H; Kitagawa Y; Miyazawa K; Fujiuchi Y; Yokoyama O
    Int J Urol; 2014 Apr; 21(4):389-94. PubMed ID: 24118296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication.
    Klutke CG; Burgio KL; Wyman JF; Guan Z; Sun F; Berriman S; Bavendam T
    J Urol; 2009 Jun; 181(6):2599-607. PubMed ID: 19375110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients.
    Wang CC; Kuo HC
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):279-284. PubMed ID: 29843924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder.
    Wang CC; Jiang YH; Kuo HC
    Low Urin Tract Symptoms; 2017 Jan; 9(1):27-32. PubMed ID: 28120445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Pharmacotherapy for Overactive Bladder on the Incidence of and Factors Related to Urinary Tract Infection: A Systematic Review and Meta-analysis.
    Tsubouchi K; Arima H; Abe M; Matsuzaki H; Tominaga K; Fujikawa A; Gunge N; Miyazaki T; Okabe Y; Nakamura N; Matsuoka H; Okutsu S; Tada K; Haga N
    J Urol; 2023 Apr; 209(4):665-674. PubMed ID: 36787147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimuscarinic Discontinuation in Patients with Overactive Bladder in Nursing Homes: A Retrospective Study of Medicare Beneficiaries.
    Aparasu RR; Sura S; Earla JR; Shiozawa A; Ng DB; Schermer CR
    Adv Ther; 2020 Aug; 37(8):3584-3605. PubMed ID: 32638205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness Tool.
    Villacampa F; Ruiz MA; Errando C; Arlandis S; Arumí D; Lizarraga I; Rejas J
    Int Urogynecol J; 2013 Apr; 24(4):573-81. PubMed ID: 23111865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antimuscarinic drug therapy for overactive bladder syndrome in the elderly - are the concerns justified?
    Khastgir J
    Expert Opin Pharmacother; 2019 May; 20(7):813-820. PubMed ID: 30724647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year.
    Hsiao SM; Lin HH; Kuo HC
    Low Urin Tract Symptoms; 2018 Jan; 10(1):21-26. PubMed ID: 27515567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled analysis of the efficacy and safety of tibial nerve stimulation versus antimuscarinic agents in the management of overactive bladder syndrome.
    Xia L; Yan H; Sun Y; Zhu Y; Wu Y; Chen Z; Su S
    Medicine (Baltimore); 2021 Nov; 100(45):e27745. PubMed ID: 34766587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
    Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A
    Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender specific pharmacokinetic and pharmacodynamic considerations for antimuscarinic drugs for overactive bladder treatment.
    Hartigan SM; Dmochowski RR
    Expert Opin Drug Metab Toxicol; 2020 Feb; 16(2):103-110. PubMed ID: 31918590
    [No Abstract]   [Full Text] [Related]  

  • 20. Health Related Quality of Life in Patients with Side-Effects after Antimuscarinic Treatment for Overactive Bladder.
    Kim A; Lee KS; Jung R; Na S; Kim JC; Kim HG; Choo MS
    Low Urin Tract Symptoms; 2017 Sep; 9(3):171-175. PubMed ID: 27291463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.